No connection

Search Results

ATRA vs PLUR

ATRA
Atara Biotherapeutics, Inc.
BEARISH
Price
$5.22
Market Cap
$37.6M
Sector
Healthcare
AI Confidence
85%
PLUR
Pluri Inc.
BEARISH
Price
$3.51
Market Cap
$35.3M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ATRA
1.83
PLUR
--
Forward P/E
ATRA
11.66
PLUR
-1.85
P/B Ratio
ATRA
-1.03
PLUR
-2.4
P/S Ratio
ATRA
0.25
PLUR
26.35
EV/EBITDA
ATRA
0.91
PLUR
-2.58

Profitability

Gross Margin
ATRA
46.76%
PLUR
40.63%
Operating Margin
ATRA
-102.72%
PLUR
-3285.86%
Profit Margin
ATRA
15.4%
PLUR
0.0%
ROE
ATRA
--
PLUR
--
ROA
ATRA
30.86%
PLUR
-50.6%

Growth

Revenue Growth
ATRA
-91.4%
PLUR
7.0%
Earnings Growth
ATRA
--
PLUR
--

Financial Health

Debt/Equity
ATRA
--
PLUR
--
Current Ratio
ATRA
1.02
PLUR
0.43
Quick Ratio
ATRA
0.86
PLUR
0.39

Dividends

Dividend Yield
ATRA
--
PLUR
--
Payout Ratio
ATRA
0.0%
PLUR
0.0%

AI Verdict

ATRA BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.

Strengths
Recent quarterly earnings have consistently beaten estimates, with an average surprise of +242% over the last four quarters
Gross margin remains relatively strong at 46.76%, suggesting some pricing power or cost control in core operations
Current price of $5.22 is significantly below the growth-based intrinsic value estimate of $20.02, implying potential upside if fundamentals stabilize
Risks
Piotroski F-Score of 2/9 indicates very weak financial health, with red flags across profitability, leverage, and operating efficiency
Operating margin of -102.72% reflects unsustainable cost structure and lack of path to profitability
Revenue has collapsed by 91.4% year-over-year, signaling severe commercial or operational challenges
PLUR BEARISH

PLUR exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.40, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a current ratio of 0.43, suggesting it cannot meet its short-term obligations. While recent quarterly earnings have beaten estimates, the operating margin of -3285.86% and a bearish technical trend (0/100) underscore a high risk of insolvency or significant shareholder dilution. The valuation is disconnected from fundamentals, trading at a high Price/Sales multiple of 26.35 despite sluggish revenue growth.

Strengths
Recent quarterly earnings beats (3 of last 4 quarters)
Positive YoY EPS growth (+71%)
Gross margin remains positive at 40.63%
Risks
Negative equity (P/B -2.40) indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.43)
Catastrophic operating losses (-3285.86% margin)

Compare Another Pair

ATRA vs PLUR: Head-to-Head Comparison

This page compares Atara Biotherapeutics, Inc. (ATRA) and Pluri Inc. (PLUR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile